CD-47 targeting therapeutics market

  Since the approval of Enbrel® in 1998 for the treatment of rheumatoid arthritis, Fc fusion therapies have evolved into a prominent class of therapeutics; currently, several therapies are being developed for a variety of disease indications   London   Roots Analysis has announced the addition of “ Fc Fusion Therapeutics Market , 2021-2030” report to its list of offerings.   With 13 drugs approved in the European Union and the US, Fc fusion therapeutics are considered to be one of the most successful classes of IgG-based products. The success of these biopharmaceutical products can be attributed to their diverse biological and pharmacological properties, including an extended serum half-life, enhanced Fc mediated effector functions, easy expression, increased stability and aggregation resistance, modulated immunogenicity and improved safety profiles, for the treatment of a wide range of disease indications   To order this 130+ page report, wh...

  Exponential increase in amount of digital data being generated, coupled to the limitations of conventional storage mediums, has created a need for sustainable storage options and DNA data storage has garnered significant interest as an alternative   London   Roots Analysis has announced the addition of DNA Data Storage Market, 2021-2035” report to its list of offerings.   DNA as a data storage medium helps eliminate the drawbacks inherent to the traditional storage methods, such as limited storage density, instability and limited life span, making it a potential storage option for future. However, exorbitant costs, slow speed of reading and writing DNA and vulnerability to mutations or errors, may act as a roadblock in the wider use of DNA as an effective data storage solution, which has prompted the stakeholders to focus on improvements in various steps involved in DNA data storage, including data encoding, DNA synthesis, preservation, data retriev...

  Upon realizing the potential of this novel target, industry stakeholders have initiated several R&D efforts focused on exploiting the use of CD47 as an effective biomarker for the diagnosis and treatment purposes.   Roots Analysis has announced the addition of “ CD-47 Targeting Therapeutics Market, 2021-2035 ” report to its list of offerings.   In recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. CD-47 , owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker.   To order this 190+ page report, which features 142+ figures, please visit https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html   Key Market Insights   Over 75 CD-47 drug candidates are under various phases of development 52% of the pipeline candidates are cu...